Pluripotent Stem Cells
Platform to Culture Cardiomyocytes Derived from Human Pluripotent Stem Cells
Inventors: Wendy Crone, Brett Napiwocki, Max Salick
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing an improved platform to study cardiomyocytes derived from human pluripotent stem cells for basic research, drug discovery and tissue engineering
Cardiomyocytes derived from human pluripotent stem cells (hPSC-CMs) have many uses in basic research, drug discovery and tissue engineering. However, differentiated cardiomyocytes often do not exhibit natural characteristics in vitro. The inventors have developed an improved laboratory platform that matures hPSC-CMs to better reflect the properties of adult CMs found in vivo. The platform combines micropatterned chemistries with well-defined cell adhesion substrates and pure human cardiomyocyte cultures to produce an optimized platform for the study and use of cardiomyocytes. In contrast to other methods, human cardiomyocytes seeded onto these patterns enlarge, elongate and produce fiber structures that mimic the fibrous structure of the native myocardium.
- Cardiomyocytes derived using this platform better mimic natural cardiomyocytes and could be used for basic stem cell research and disease modeling, drug discovery and tissue engineering.
- Cells are highly aligned, highly structured cardiomyocyte aggregates that closely mimic cardiomyocyte behavior in vivo.
- Cells are of better size and have increased aspect ratio with much improved sarcomere structure.
Stage of Development
The inventors have developed the physical platform and demonstrated that cardiomyocytes derived in this manner exhibit many beneficial attributes. Functional studies including optical mapping indicated improvements in maturation and the correct physiological response to beta-adrenergic stimulation. More work would be needed to produce this platform in quantity.
For More Information About the Inventors